Auzerie J, Colle M, Guinot P, Lavergne V
Centre d'exploration endocrinologique, Bordeaux, France.
Arch Pediatr. 1995 Apr;2(4):365-72. doi: 10.1016/0929-693x(96)81160-2.
Results of clinical trials performed with human hypothalamic growth hormone releasing factor (GRF) are conflicting, but rather disappointing for most of them. Pulsatile administration of GRF has been found to increase growth hormone secretion as well as growth velocity, but is not convenient for practical use. All other routes and rhythms of administration lead only to sub-optimal results, and generally does not seem to procure an appropriate GRF bio-availability. Improvements are possible, particularly the development of agonists and new galenic forms with sustained release. Therapeutic approach with hexapeptides, or hexapeptides analogs, looks promising, but could be more complementary than competitive.
